

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : J. Guy Breitenbucher

Serial No.: 10/075,673

Art Unit: 1617

Filed

: February 13, 2002

Examiner: Shengjun Wang

For

: Method for Treating Allergies Using Subsituted

Pyrazoles

I hereby certify that this correspondence is being deposited with the United States Postal Service as US Express Mail label number EV528208551US in an envelope addressed to: Mail Stop RCE, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

(Date of Deposit)

VESUS VIMMOS 1 TIMONEDA

Name of applicant, assignee, or Registered Representative)

Marcoula 6, 2006

(Date of Signature)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

In accordance with §1.97(b), since this Information \boxtimes Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with \(\square\$ the first or second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with \$1.97(e)
(attached); or
Please charge Deposit Account No. 10-
0750/ / the fee of $$180.00$ as set forth
in §1.17(p).
☐ In accordance with §1.97(d), this Information
Disclosure Statement is being filed after the mailing date of
either a Final Action under §1.113 or a Notice of Allowance
under §1.311 but before the payment of the Issue Fee.
Applicant(s) hereby petition(s) for consideration of this
Information Disclosure Statement. Included are: Statement in
Accordance with §1.97(e) as set forth below and the fee of
\$180.00 as set forth in §1.17(p).
Copies of each of the references listed on the
attached Form PTO-1449 are enclosed herewith.
Copies of references listed on the attached Form PTO
1449 are enclosed herewith EXCEPT THAT:
In view of the voluminous nature of references
[list as appropriate], and the likelihood that
these references are available to the Examiner,
copies are not enclosed herewith.
- '
<pre>If any of the foregoing publications are not</pre>
available to the Examiner, Applicant will
endeavor to supply copies at the Examiner's
request.
☐ Copies of only foreign patent documents and non-
patent literature are enclosed in accordance with 37 CFR 1.98
(a) (2).

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/ORT1590/JJT. This form is submitted in triplicate.

Respectfully submitted,

Jesus Juanos i Timoneda

Req. No. 43,332

Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(858) 320-3549



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information diffess it displays a valid clinic control familier.			
Application Number	10/075,673		
Filing Date	February 13, 2002		
First Named Inventor	J. Guy Breitenbucher		
Group Art Unit	1617		
Examiner Name	Shengjun Wang		
Attorney Docket Number	ORT-1590		

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Document Kind Code ²		Name of Patentee or Applicant	Date of Publication	Pages, Columns, Lines,
		h *		known)	of Cited Document .	of Cited Document mm-dd-yyyy
		5,830,850	Α	Gelb et al.	11-03-1998	
		6,214,813	B1	Zhang et al.	04-10-2001	
		2002/0040020	A1	Breitenbucher et al.	04-04-2002	
				<u>-</u>		
				. =	·	
				·		

Foreign Patent Document Pages, Columns, Lines, where Date of Publication of Cited Document relevant passages or relevant Name of Patentee Cite figures appear Examiner ornce³ Number⁴ KindCode⁵ mm-dd-yyyy T⁶ Initials Applicant of Cited Document EP 0747049 12-11-1996 **A1** Eli Lilly and Company


FOREIGN PATENT DOCUMENTS

Examiner	Date	_	
Signature	Considered		

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

a collection of information diffess it displays a valid of the control fighther.			
Application Number	10/075,673		
Filing Date	February 13, 2002		
First Named Inventor	J. Guy Breitenbucher		
Group Art Unit	1617		
Examiner Name	Shengjun Wang		
Attorney Docket Number	ORT-1590		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Fujimura, Y. et al. "Indazole Derivatives" Abstract retrieved from STN	
		Database accession no. 87:53281, Chugai Pharmaceutical Co., Ltd. Japan 1977	
		Fujimura, Y. et al. "Indazole Derivatives" Abstract retrieved STN Database	
		accession no. 84:59450, Chugai Pharmaceutical Co., Ltd. Japan 1995	
-			
		·	
		·	

Examiner	•	Date	
Signature	 	Considered	 ·

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.